These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28916148)

  • 1. Chemokine receptor - Directed imaging and therapy.
    Buck AK; Stolzenburg A; Hänscheid H; Schirbel A; Lückerath K; Schottelius M; Wester HJ; Lapa C
    Methods; 2017 Nov; 130():63-71. PubMed ID: 28916148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
    Chen Z; Xue Q; Yao S
    Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
    Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCR4-targeted theranostics in oncology.
    Buck AK; Serfling SE; Lindner T; Hänscheid H; Schirbel A; Hahner S; Fassnacht M; Einsele H; Werner RA
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4133-4144. PubMed ID: 35674738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Contrast CXCR4-Targeted
    Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
    Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.
    Herhaus P; Habringer S; Philipp-Abbrederis K; Vag T; Gerngross C; Schottelius M; Slotta-Huspenina J; Steiger K; Altmann T; Weißer T; Steidle S; Schick M; Jacobs L; Slawska J; Müller-Thomas C; Verbeek M; Subklewe M; Peschel C; Wester HJ; Schwaiger M; Götze K; Keller U
    Haematologica; 2016 Aug; 101(8):932-40. PubMed ID: 27175029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.
    Vag T; Gerngross C; Herhaus P; Eiber M; Philipp-Abbrederis K; Graner FP; Ettl J; Keller U; Wester HJ; Schwaiger M
    J Nucl Med; 2016 May; 57(5):741-6. PubMed ID: 26769866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
    Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
    Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.
    Wester HJ; Keller U; Schottelius M; Beer A; Philipp-Abbrederis K; Hoffmann F; Šimeček J; Gerngross C; Lassmann M; Herrmann K; Pellegata N; Rudelius M; Kessler H; Schwaiger M
    Theranostics; 2015; 5(6):618-30. PubMed ID: 25825601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics.
    Habringer S; Lapa C; Herhaus P; Schottelius M; Istvanffy R; Steiger K; Slotta-Huspenina J; Schirbel A; Hänscheid H; Kircher S; Buck AK; Götze K; Vick B; Jeremias I; Schwaiger M; Peschel C; Oostendorp R; Wester HJ; Grigoleit GU; Keller U
    Theranostics; 2018; 8(2):369-383. PubMed ID: 29290814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
    Zhou Y; Cao HB; Li WJ; Zhao L
    Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4 Ligands: The Next Big Hit?
    Walenkamp AME; Lapa C; Herrmann K; Wester HJ
    J Nucl Med; 2017 Sep; 58(Suppl 2):77S-82S. PubMed ID: 28864616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in PET Imaging of the CXCR4 Receptor: [
    Lindenberg L; Ahlman M; Lin F; Mena E; Choyke P
    Semin Nucl Med; 2024 Jan; 54(1):163-170. PubMed ID: 37923671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
    Scala S
    Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4-directed theranostics in oncology and inflammation.
    Kircher M; Herhaus P; Schottelius M; Buck AK; Werner RA; Wester HJ; Keller U; Lapa C
    Ann Nucl Med; 2018 Oct; 32(8):503-511. PubMed ID: 30105558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
    Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
    Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [
    Schottelius M; Osl T; Poschenrieder A; Hoffmann F; Beykan S; Hänscheid H; Schirbel A; Buck AK; Kropf S; Schwaiger M; Keller U; Lassmann M; Wester HJ
    Theranostics; 2017; 7(9):2350-2362. PubMed ID: 28744319
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
    Peled A; Klein S; Beider K; Burger JA; Abraham M
    Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on CXCR4/CXCL12 axis in oncology: no place to hide.
    Domanska UM; Kruizinga RC; Nagengast WB; Timmer-Bosscha H; Huls G; de Vries EG; Walenkamp AM
    Eur J Cancer; 2013 Jan; 49(1):219-30. PubMed ID: 22683307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.